Medicare Enrolled
Dr. Leann Blankenship, M.D.
Hematology & Oncology · Pleasant Hill, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Blankenship from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Blankenship?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Blankenship
Dr. Leann Blankenship is a hematology & oncology specialist in Pleasant Hill, CA, with 14 years of NPI registration. Based on federal Medicare data, Dr. Blankenship performed 38,808 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Blankenship received a total of $18,600 from 88 pharmaceutical and/or device companies across 658 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Blankenship is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 14 years of NPI registration
▲ Top 18% volume in CA
$18,600 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗38,808
Medicare services
Top 18% in CA for hematology & oncology
Not available
Unique patients (not deduplicated)
$14
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
14,700 | $0 | $8 |
| Denosumab injection (Prolia/Xgeva) | 5,640 | $18 | $65 |
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
3,100 | $0 | $2 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,810 | $0 | $7 |
| Iron infusion (Monoferric) | 2,600 | $17 | $72 |
| MRI contrast dye injection (gadobutrol) | 2,550 | $0 | $2 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,620 | $1 | $101 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
871 | $8 | $32 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
696 | $8 | $17 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
595 | $81 | $355 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
556 | $30 | $145 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
483 | $105 | $357 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
474 | $13 | $85 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
299 | $135 | $658 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
232 | $70 | $183 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
197 | $20 | $88 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
169 | $1 | $9 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
166 | $7 | $371 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
129 | $67 | $322 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
115 | $1 | $33 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
85 | $29 | $146 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
76 | $65 | $295 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 72 | $281 | $1,141 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
67 | $27 | $110 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
66 | $1,695 | $6,785 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
59 | $151 | $513 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
55 | $104 | $264 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
52 | $162 | $461 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
49 | $147 | $458 |
| CT scan of chest, without contrast A computed tomography scan of the chest area that uses X-rays to create detailed images without the use of contrast dye. |
36 | $128 | $797 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
33 | $41 | $125 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
30 | $39 | $267 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
27 | $178 | $932 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
27 | $324 | $1,371 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
25 | $97 | $319 |
| New patient office visit, complex (60-74 min) | 18 | $206 | $611 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
17 | $35 | $225 |
| MRI scan of both breasts A magnetic resonance imaging test that creates detailed pictures of both breasts to help evaluate breast tissue. |
12 | $348 | $1,323 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
9.9% high complexity
81.2% medium
8.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$18,600
Total received (2018-2024)
Avg $2,657/year across 7 years
Top 22% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
88
Companies
658
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,317
2023
$4,392
2022
$2,923
2021
$1,611
2020
$4,277
2019
$697
2018
$383
Payments by company (2024)
PFIZER INC.
$577
AstraZeneca Pharmaceuticals LP
$333
ABBVIE INC.
$319
Takeda Pharmaceuticals U.S.A., Inc.
$287
GlaxoSmithKline, LLC.
$272
Novartis Pharmaceuticals Corporation
$180
Celgene Corporation
$169
Merck Sharp & Dohme LLC
$159
Janssen Biotech, Inc.
$137
Gilead Sciences, Inc.
$136
E.R. Squibb & Sons, L.L.C.
$129
ARRAY BIOPHARMA INC
$101
EMD Serono, Inc.
$100
Karyopharm Therapeutics Inc.
$90
Incyte Corporation
$85
Daiichi Sankyo Inc.
$82
Octapharma USA, Inc.
$72
SERVIER PHARMACEUTICALS LLC
$68
Stemline Therapeutics Inc.
$66
Regeneron Healthcare Solutions, Inc.
$66
Astellas Pharma US Inc
$57
SpringWorks Therapeutics, Inc.
$57
GENZYME CORPORATION
$56
Eisai Inc.
$54
Boehringer Ingelheim Pharmaceuticals, Inc.
$54
Genentech USA, Inc.
$51
TAIHO ONCOLOGY, INC.
$50
Exelixis Inc.
$46
JAZZ PHARMACEUTICALS INC.
$38
Deciphera Pharmaceuticals Inc.
$37
Ipsen Biopharmaceuticals, Inc
$33
Geron Corporation
$33
SOBI, INC
$33
Blueprint Medicines Corporation
$30
PUMA BIOTECHNOLOGY, INC.
$26
Agios Pharmaceuticals, Inc.
$25
Genmab U.S., Inc.
$25
Kyowa Kirin, Inc.
$22
Tactile Systems Technology Inc
$22
BeiGene USA, Inc.
$22
Myriad Genetic Laboratories, Inc.
$21
Acrotech Biopharma Inc.
$21
Apellis Pharmaceuticals, Inc.
$21
Kite Pharma, Inc.
$20
SUN PHARMACEUTICAL INDUSTRIES INC.
$19
Bayer Healthcare Pharmaceuticals Inc.
$18
Top 3 companies account for 28.5% of 2024 payments
All-time payments by company (2018-2024) ›
Agios Pharmaceuticals, Inc.
$4,164
PFIZER INC.
$1,151
AstraZeneca Pharmaceuticals LP
$1,080
Novartis Pharmaceuticals Corporation
$887
Amgen Inc.
$664
E.R. Squibb & Sons, L.L.C.
$629
GlaxoSmithKline, LLC.
$598
Astellas Pharma US Inc
$507
Takeda Pharmaceuticals U.S.A., Inc.
$473
Janssen Biotech, Inc.
$467
Merck Sharp & Dohme LLC
$461
Seagen Inc.
$436
Celgene Corporation
$432
GENZYME CORPORATION
$397
ABBVIE INC.
$346
Kite Pharma, Inc.
$320
ARRAY BIOPHARMA INC
$318
Gilead Sciences, Inc.
$300
Genentech USA, Inc.
$289
Daiichi Sankyo Inc.
$230
Lilly USA, LLC
$229
Eisai Inc.
$219
SANOFI-AVENTIS U.S. LLC
$177
Regeneron Healthcare Solutions, Inc.
$171
Tactile Systems Technology Inc
$163
Foundation Medicine, Inc.
$153
TAIHO ONCOLOGY, INC.
$148
Octapharma USA, Inc.
$147
Pharmacyclics LLC, An AbbVie Company
$137
Incyte Corporation
$137
EMD Serono, Inc.
$136
Myovant Sciences Inc.
$114
Boehringer Ingelheim Pharmaceuticals, Inc.
$110
SERVIER PHARMACEUTICALS LLC
$109
Exelixis Inc.
$101
Stemline Therapeutics Inc.
$95
Pharmacosmos Therapeutics Inc.
$93
Kyowa Kirin, Inc.
$91
Karyopharm Therapeutics Inc.
$90
SOBI, INC
$81
Taiho Oncology, Inc.
$78
BeiGene USA, Inc.
$75
JAZZ PHARMACEUTICALS INC.
$75
Merck Sharp & Dohme Corporation
$68
Bayer Healthcare Pharmaceuticals Inc.
$65
Rigel Pharmaceuticals, Inc.
$64
Acrotech Biopharma Inc.
$63
Pharmacyclics LLC, an AbbVie Company
$63
Mirati Therapeutics, Inc.
$62
Apellis Pharmaceuticals, Inc.
$62
Bayer HealthCare Pharmaceuticals Inc.
$60
Deciphera Pharmaceuticals Inc.
$58
SpringWorks Therapeutics, Inc.
$57
PUMA BIOTECHNOLOGY, INC.
$49
MorphoSys, US Inc.
$47
Ethicon US, LLC
$47
Myriad Genetic Laboratories, Inc.
$44
Epizyme, Inc.,
$34
Ipsen Biopharmaceuticals, Inc
$33
Geron Corporation
$33
PharmaEssentia USA Corporation
$32
Alexion Pharmaceuticals, Inc.
$31
EISAI INC.
$31
AbbVie Inc.
$31
Blueprint Medicines Corporation
$30
AVEO Pharmaceuticals, Inc.
$29
TerSera Therapeutics LLC
$28
TESARO, Inc.
$28
Servier Pharmaceuticals LLC
$25
Genmab U.S., Inc.
$25
Global Blood Therapeutics, Inc.
$24
Dova Pharmaceuticals
$24
CTI BioPharma Corp.
$24
Coherus Biosciences Inc.
$23
Aveo Pharmaceuticals, Inc.
$23
Clovis Oncology, Inc.
$20
SUN PHARMACEUTICAL INDUSTRIES INC.
$19
ADC Therapeutics America, Inc.
$18
Acrotech Biopharma LLC
$17
Blue Earth Diagnostics Limited
$17
Puma Biotechnology, Inc.
$17
Heron Therapeutics, Inc.
$17
AbbVie, Inc.
$17
Organon LLC
$17
Helsinn Therapeutics (U.S.), Inc.
$16
AMAG Pharmaceuticals, Inc.
$11
Verastem, Inc.
$11
Janssen Pharmaceuticals, Inc
$9
Top 3 companies account for 34.4% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AKYNZEO · ALUNBRIG · AYVAKIT · Alecensa · Axumin · BELEODAQ · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · CABOMETYX · CALQUENCE · COSELA · CYRAMZA · Cabometyx · Copiktra · DARZALEX · Doptelet · ELITEK · ELREXFIO · ENHERTU · EPKINLY · ERLEADA · Empaveli · Enhertu · Epkinly · FARESTON · FERAHEME · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · Flexitouch Plus · GAZYVA · GILOTRIF · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · JAKAFI · JAYPIRCA · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MONOFERRIC · MYRISK · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OGSIVEO · OJJAARA · ONTRUZANT · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Odomzo · Onivyde · Orserdu · PADCEV · PANZYGA · PLUVICTO · POLIVY · POTELIGEO · PRECISETUMOR · PROMACTA · PYRUKYND · Padcev · Phesgo · Polivy · Pomalyst · Poteligeo · QINLOCK · REBLOZYL · RYBREVANT · RYTELO · SARCLISA · SCEMBLIX · SUSTOL · Stivarga · TABRECTA · TAGRISSO · TALZENNA · TASIGNA · TAZVERIK · TEPMETKO · TIBSOVO · TUKYSA · Tavalisse · Tecentriq · Tibsovo · Trodelvy · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · VISTASEAL · VONJO · Vectibix · Venclexta · Vitrakvi · Vonjo · Voranigo · XALKORI · XARELTO · XOSPATA · XPOVIO · XTANDI · Xofigo · Xospata · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · Zoladex
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
105
County median income
$125,727
Nearest hospital to ZIP centroid (approximate)
JOHN MUIR MEDICAL CENTER - CONCORD CAMPUS
3.5 mi
3.5 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Blankenship is a mixed practice specialist, with above-average Medicare volume (top 18% in CA).
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Blankenship experienced with anti-nausea injection (fosaprepitant)?
Based on Medicare claims data, Dr. Blankenship performed 14,700 anti-nausea injection (fosaprepitant) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Blankenship receive payments from pharmaceutical companies?
Yes. Dr. Blankenship received a total of $18,600 from 88 companies across 658 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Blankenship's costs compare to other hematology & oncology specialists in Pleasant Hill?
Dr. Blankenship's average Medicare payment per service is $14. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Blankenship) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Pleasant Hill
Browse hematology & oncology specialists in Pleasant Hill ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Agios Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Agios Pharmaceuticals, Inc.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology